Want to see DRTS full AI Analyst Report?
Top Page
Alpha Tau Medical Ltd
(NASDAQ:DRTS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$14.50
▲(16.00% Upside)
Action:Reiterated
Date:07/01/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and significant ongoing cash burn) and limited valuation support (negative P/E, no dividend yield provided). This is partially offset by constructive technical trend signals, with the stock trading above its 20/50/100/200-day moving averages.
Positive Factors
Long-term U.S. commercial partnership
Tolmar provides a durable commercialization pathway, manufacturing support, strategic capital and access to established urology infrastructure, reducing the burden of building a U.S. sales platform alone.
Negative Factors
No demonstrated revenue base
The absence of reported revenue shows Alpha Tau remains pre-commercial, leaving future value dependent on successful trials, approvals, manufacturing scale-up and eventual market adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term U.S. commercial partnership
Tolmar provides a durable commercialization pathway, manufacturing support, strategic capital and access to established urology infrastructure, reducing the burden of building a U.S. sales platform alone.
Read all positive factors
Alpha Tau Medical Ltd (DRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.29B
Dividend YieldN/A
Average Volume (3M)751.50K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth-115.15%
CountryUS
Employees121
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.04
Shares Outstanding90,325,874
10 Day Avg. Volume654,776
30 Day Avg. Volume751,504
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.67Price Target Upside9.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$1.23M
Alpha Tau Medical Ltd Business Overview & Revenue Model
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT techno...
How the Company Makes Money
null...
Alpha Tau Medical Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.23M | -1.10M | -1.07M | -979.00K | -776.00K |
| EBITDA | -49.54M | -41.06M | -30.30M | -28.03M | -32.74M | -13.21M |
| Net Income | -92.57M | -42.63M | -31.75M | -29.16M | -33.76M | -27.27M |
Balance Sheet | ||||||
| Total Assets | 134.25M | 106.58M | 86.20M | 107.39M | 120.15M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 100.64M | 76.90M | 59.60M | 81.79M | 104.53M | 31.32M |
| Total Debt | 15.15M | 13.73M | 12.54M | 13.28M | 5.19M | 53.96M |
| Total Liabilities | 90.19M | 29.48M | 23.54M | 22.91M | 14.49M | 76.99M |
| Stockholders Equity | 44.05M | 77.10M | 62.67M | 84.47M | 105.66M | -34.78M |
Cash Flow | ||||||
| Free Cash Flow | -32.76M | -32.76M | -22.02M | -24.36M | -24.78M | -14.74M |
| Operating Cash Flow | -26.68M | -26.68M | -19.78M | -17.96M | -23.88M | -11.81M |
| Investing Cash Flow | -20.59M | -20.59M | 20.77M | 18.68M | -89.94M | 19.27M |
| Financing Cash Flow | 45.77M | 45.77M | 25.00K | 5.30M | 96.91M | 111.00K |
Alpha Tau Medical Ltd Technical Analysis
Positive
12.50
Price Trends
12.14
Positive
10.38
Positive
8.14
Positive
Market Momentum
0.64
Negative
63.80
Neutral
75.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRTS, the sentiment is Positive. The current price of 12.5 is below the 20-day moving average (MA) of 13.11, above the 50-day MA of 12.14, and above the 200-day MA of 8.14, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 63.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRTS.
Alpha Tau Medical Ltd Risk Analysis
Alpha Tau Medical Ltd disclosed 81 risk factors in its most recent earnings report. Alpha Tau Medical Ltd reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alpha Tau Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $421.76M | -2.14 | -137.39% | ― | ― | -27.00% | |
52 Neutral | $1.29B | -13.91 | -138.12% | ― | ― | -115.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $404.49M | -4.67 | -41.85% | ― | ― | 64.51% | |
46 Neutral | $411.62M | -3.26 | -59.27% | ― | -100.00% | -49.28% | |
39 Underperform | $846.23M | -4.38 | -73.18% | ― | ― | 9.05% | |
37 Underperform | $442.48M | -12.05 | -34.82% | ― | ― | 41.21% |
* Healthcare Sector Average
DRTS
Alpha Tau Medical Ltd
14.47
11.41
372.88%
LRMR
Larimar Therapeutics
4.25
0.48
12.73%
CAPR
Capricor Therapeutics
7.98
0.81
11.30%
BNTC
Benitec Biopharma
13.38
0.50
3.88%
AURA
Aura Biosciences Inc
7.79
1.42
22.29%
LXEO
Lexeo Therapeutics, Inc.
5.37
0.57
11.88%
Alpha Tau Medical Ltd Corporate Events
Alpha Tau Medical Updates Investors With H1 2026 Financials in New Form 6-K Filing
Aug 10, 2026
On August 10, 2026, Alpha Tau Medical Ltd. filed a Form 6-K with U.S. regulators, providing unaudited interim consolidated financial statements as of June 30, 2026 and an operating and financial review for the first half of 2026. The filing, which...
Alpha Tau Medical Registers for Dual Listing on Tel Aviv Stock Exchange
Aug 10, 2026
Alpha Tau Medical Ltd., an Israeli oncology therapeutics company founded in 2016, develops the Alpha DaRT alpha-radiation therapy for solid tumors, aiming to destroy tumors while limiting damage to healthy tissue. The firm’s technology origi...
Alpha Tau Posts Strong Alpha DaRT–Keytruda Data in Head and Neck Cancer Study
Jul 21, 2026
Alpha Tau Medical Ltd., a Jerusalem-based developer of the Alpha DaRT alpha-radiation cancer therapy, is advancing a pipeline across head and neck, skin, pancreatic, prostate and brain cancers. Listed on Nasdaq under DRTS and DRTSW, the company is...
Alpha Tau Medical Shareholders Back Board, CEO Dual Role and Auditor at June 2026 AGM
Jun 25, 2026
On June 23, 2026, Alpha Tau Medical Ltd. held its Annual General Meeting of Shareholders in Jerusalem, where investors voted on a slate of governance and compensation matters. Shareholders re-elected directors David Milch and Ruth Alon to Class II...
Alpha Tau Treats First Recurrent Glioblastoma Patient Outside U.S. With Alpha DaRT in Israel
Jun 23, 2026
Alpha Tau Medical Ltd., a Jerusalem-based oncology company listed on Nasdaq, specializes in Alpha DaRT, a diffusing alpha-emitters radiation therapy for solid tumors that uses stereotactic, minimally invasive delivery systems, including brain-spec...
Alpha Tau Wins FDA Clearance to Complete REGAIN Glioblastoma Trial Enrollment After Strong Interim Data
Jun 11, 2026
On June 11, 2026, Alpha Tau Medical announced that the U.S. Food and Drug Administration cleared it to complete enrollment of the remaining seven patients in its REGAIN trial for recurrent glioblastoma, after reviewing a pre-specified interim safe...
Alpha Tau Strikes 20-Year U.S. Prostate Cancer Commercialization and $20 Million Equity Deal With Tolmar
Jun 3, 2026
On June 2, 2026, Alpha Tau Medical Ltd. and its U.S. subsidiary signed a long-term collaboration and supply deal with Tolmar International Ltd., giving Tolmar exclusive rights to commercialize Alpha DaRT for prostate cancer in the United States. T...
Alpha Tau Posts Strong Pancreatic Cancer Survival Data for Alpha DaRT at 2026 ASCO
Jun 1, 2026
On June 1, 2026, Alpha Tau reported positive overall survival and safety data from a pooled analysis of three Phase I/II trials of its endoscopic ultrasound-guided Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic duc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.